AFP and neoplasm: The patients that benefitted the most according to the subgroup analysis were patients > 60 years old; those with lower levels of AFP (≤400 ng/mL); more than three tumors, with the largest tumor size < 4 cm; and those without hepatitis B infection and liver cirrhosis.